<DOC>
	<DOCNO>NCT00982566</DOCNO>
	<brief_summary>This randomize , single dose , open-label , multicenter crossover study determine oral bioavailability new ABT-263 formulation relative current ABT-263 formulation administer ongoing Phase 1/2a study . Approximately 48 evaluable subject lymphoid malignancy , include chronic lymphocytic leukemia , solid tumor enrol study .</brief_summary>
	<brief_title>Assess Oral Bioavailability New ABT-263 Formulation Subjects With Cancer</brief_title>
	<detailed_description>Subjects complete Part 1 study provide opportunity receive Formulation A continuous daily dose schedule Part 2 study . Subjects enrol second part study may continue receive Formulation A continuous daily dose schedule one year follow date last subject enrol study provide continue tolerate drug , evidence disease progression , meet protocol specific criterion subject discontinuation .</detailed_description>
	<mesh_term>Navitoclax</mesh_term>
	<criteria>1 . Subject must &gt; = 18 year age . 2 . Subject lymphoid malignancy ( histologic cytologic confirmation ) , solid tumor ( radiographic , histologic , cytologic confirmation ) either : relapsed refractory standard therapy , know effective therapy exists . 3 . In investigator 's opinion , subject 's life expectancy least 90 day . 4 . Subjects know brain metastasis must clinically control neurologic symptom , define surgical excision and/or radiation therapy follow 21 day stable neurologic function evidence CNS disease progression determine CT MRI within 21 day prior first dose study drug . 5 . If clinically indicate , subject must document brain imaging ( MRI CT ) negative subdural epidural hematoma within 28 day prior first dose study drug . 6 . Subject Eastern Cooperative Oncology Group ( ECOG ) performance score &lt; = 2 . 7 . Subject must adequate bone marrow , renal hepatic function per local laboratory reference range follow : Bone marrow : Absolute Neutrophil count ( ANC ) &gt; = 1,000/ÂµL ; Platelets &gt; = 100,000/mm3 ( independent platelet transfusion within 3 month prior start study drug ) ; Hemoglobin &gt; = 9.0 g/dL ; Renal function : serum creatinine &lt; = 2.0 mg/dL calculate creatinine clearance &gt; = 50 mL/min ; Hepatic function enzyme : AST ALT &lt; = 2.5 x upper normal limit ( ULN ) institution 's normal range ; Bilirubin &lt; = 1.5 x ULN . Subjects Gilbert 's Syndrome may Bilirubin &gt; 1.5 x ULN ; Subjects liver metastasis may AST ALT &lt; = 5.0 x ULN ; Coagulation : aPTT , PT exceed 1.2 x ULN . 8 . Female subject must surgically sterile , postmenopausal ( least one year ) , negative result pregnancy test perform follow : At Screening serum sample obtain within 14 day prior initial study drug administration , Prior start dose urine sample &gt; 7 day since obtain serum pregnancy test result . 9 . Female subject surgically sterile postmenopausal ( least one year ) nonvasectomized male subject must practice least one follow method birth control : total abstinence sexual intercourse ( minimum one complete menstrual cycle prior start study drug ) ; vasectomize partner ; hormonal contraceptive ( oral , parenteral transdermal ) least three month prior study drug administration ; doublebarrier method ( include condom , contraceptive sponge , diaphragm vaginal ring spermicidal jelly cream ) . 10 . Subject must voluntarily sign date inform consent , approve Independent Ethics Committee ( IEC ) /Institutional Review Board ( IRB ) , prior initiation screen studyspecific procedure . 1 . Subject undergone allogeneic stem cell transplant . 2 . Subject underlying condition predispose bleed currently exhibit sign clinically significant bleeding . 3 . Subject recent history nonchemotherapy induce thrombocytopenic associate bleeding within one year prior first dose study drug . 4 . Subject active peptic ulcer disease hemorrhagic esophagitis/gastritis . 5 . Subject significant history cardiovascular disease ( e.g. , MI , thrombotic thromboembolic event last 6 month ) , renal , neurologic , psychiatric , endocrinologic , metabolic , immunologic , hepatic disease opinion investigator would adversely affect his/her participate study . Questions regard inclusion individual subject direct Abbott Medical Monitor designee . 6 . Female subject pregnant breastfeeding . 7 . Subject history active medical condition ( ) affect absorption motility ( e.g. , Crohn 's disease , celiac disease , gastroparesis , short bowel syndrome , etc. ) . 8 . Subject test positive HIV ( due potential drugdrug interaction anti retroviral inhibitor ABT263 , well anticipate ABT263 mechanism base lymphopenia may potentially increase risk opportunistic infection potential drugdrug interaction certain anti infective agent ) . 9 . Subject exhibit evidence clinically significant uncontrolled condition ( ) include , limited : active systemic fungal infection ; diagnosis fever neutropenia within one week prior study drug administration . 10 . Subject receive follow anticancer therapy 14 day prior first dose study drug , recover less grade 2 clinically significant adverse effect ( ) /toxicity ( ) previous therapy : chemotherapy , immunotherapy , radiotherapy ; hormonal therapy ( exception hormone hypothyroidism estrogen replacement therapy [ ERT ] , agonists required suppress serum testosterone level [ e.g. , LHRH , GnRH , etc . ] subject prostate cancer stable dose 21 day prior first dose study drug ) ; investigational therapy , include target small molecule agent 11 . Subject receive biologic agent antineoplastic intent within 30 day prior first dose study drug . 12 . Subject currently receive require anticoagulation therapy drug herbal supplement affect platelet function , exception lowdose anticoagulation medication , heparin , use maintain patency central intravenous catheter . Note , warfarin exclude dose level . 13 . Subject receive aspirin within 7 day prior first dose study drug ABT263 administration . 14 . Subject consume grapefruit grapefruit product within 3 day prior first dose study drug . 15 . In opinion investigator , subject unsuitable candidate receive ABT263 . 16 . Subject receive CYP3A inducer within 7 day prior first dose study drug ABT263 administration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>